HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market News: FTC Targets Bone Health Claims, Puration Offers To Buy Hemp4mula, More

Executive Summary

FTC settled with one firm and is pursuing litigation against another after alleging claimed supplements could grow bone and cartilage; CBD beverage firm Puration offers to acquire Hemp4mula; and Huron Capital’s Ronnoco Beverage business acquires Trident Beverage.

You may also be interested in...



Memory Health Marketer Reminded About Brain Health Ad Claims Substantiation In NAD Review

Michigan firm likely remembered burden for substantiating health as well as structure/function claims under FDA regulations for supplements after NAD reviewed its ad materials presented online, in videos and in news releases submitted by Vision Elements.

Hydrolyzed Collagen Supplement Firm Agrees To Order Barring Claims To Grow Bone, Cartilage

Claims of bone and cartilage growth, along with relief of joint pain, shot down by FTC. But company says claims “are adequately substantiated by existing studies and scientific literature.”

Puration On CBD Space Spending Spree, But It's Not Alone Sensing Fertile Ground For Expansion

Puration plans to acquire CBD-based sun care and sexual wellness lines on a buying spree in what appears to be a fertile market for deals. Aurora Cannabis and Applied Botanics also are making moves to work with smaller businesses in the CBD sector.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel